The Biostatistics, Data Management, and Bioinformatics Core forthe University of Texas M.D. Anderson Cancer Center Leukemia SPORE will be a comprehensive, multilateral resource for data acquisition and management, design of laboratory experiments and clinical trials, development of innovative statistical methodology, statistical analysis, and publishing translational research generated through the Leukemia SPORE program. The Biostatistics, Data Management, and Bioinformatics Core will incorporate sound experimental design principles within all Projects, will carry out data analyses using appropriate statistical methodology, and will contribute to interpretation of results through written reports and frequent interaction with Project investigators. The Biostatistics, Data Management, and Bioinformatics Core will provide an integrated data management system to facilitate communication among all Projects and Cores, which will be customized to meet the needs of the Department of Leukemia. This process includes prospective data collection, data quality control, data security, and patient confidentiality. Thus, from inception to reporting, translational experiments will benefit from SPORE resources that will be used to augment existing M. D. Anderson biostatistics resources.

Public Health Relevance

Effective biostatistical consultation and collaboration on the design, conduct, analysis, and interpretation of research studies increases the likelihood that such studies will achieve their objectives, and that valid conclusions will be drawn. Utilization of appropriate biostatistical models and methods in the preparation of reports and interpretation of studies is essential to reaching correct conclusions and to ensure the publication of results in appropriate journals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-11
Application #
8499757
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2013-05-01
Project End
2018-08-31
Budget Start
2013-09-13
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$155,020
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Issa, Jean-Pierre; Garcia-Manero, Guillermo; Huang, Xuelin et al. (2015) Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121:556-61
Huang, Xuelin; Ning, Jing; Wahed, Abdus S (2014) Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med 33:2363-78
Yousefzadeh, Matthew J; Wyatt, David W; Takata, Kei-Ichi et al. (2014) Mechanism of suppression of chromosomal instability by DNA polymerase POLQ. PLoS Genet 10:e1004654
Grunwald, Michael R; Tseng, Li-Hui; Lin, Ming-Tseh et al. (2014) Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Biol Blood Marrow Transplant 20:1989-95
Su, Xiaoping; Malouf, Gabriel G; Chen, Yunxin et al. (2014) Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 5:9864-76
Chae, Young Kwang; Dimou, Anastasios; Pierce, Sherry et al. (2014) The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma 55:2822-9
Konig, Heiko; Levis, Mark (2014) Is targeted therapy feasible in acute myelogenous leukemia? Curr Hematol Malig Rep 9:118-27
Galanis, Allison; Ma, Hayley; Rajkhowa, Trivikram et al. (2014) Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 123:94-100
Bottoni, Arianna; Calin, George A (2014) MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. Microrna 2:158-64
Zhang, Yun; Xiong, Shunbin; Li, Qin et al. (2014) Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 233:380-91

Showing the most recent 10 out of 222 publications